MBIO
Mustang Bio, Inc.
stockNASDAQ
mustang bio, inc., a subsidiary of fortress biotech, inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient's own immune system to eliminate cancer cells. mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. mustang has partnered with the city of hope national medical center ("coh") and fred hutchinson cancer research center in the development of proprietary chimeric antigen receptor (car) engineered t cell (car t) therapies across many cancers. mustang's lead programs are in phase 1 clinical trials at coh: mb-101 for the treatment of brain cancer and mb-102 as a therapeutic agent in acute myeloid leukemia.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.41 | 2026-11-03 | +10.09% | 0.751 |
| 1M | 0.40 | 2026-10-09 | +12.65% | 0.559 |
| 3M | 0.59 | 2026-08-10 | -23.62% | 0.583 |
| 6M | 0.66 | 2026-05-11 | -31.71% | 0.638 |
| 1Y | 1.23 | 2025-11-10 | -63.36% | 1.016 |
| 2Y | 12.85 | 2024-11-11 | -96.49% | — |
| 5Y | 1,860.00 | 2021-11-10 | -99.98% | 1.453 |
Mustang Bio, Inc. (NASDAQ:MBIO) stock price today is $0.45, and today's volume is 181,652. MBIO is up 15.151% today. The 30 day average volume is 36,453. MBIO market cap is $3.42M with 7.58M shares outstanding.